Immunotherapy / PD-1 inhibitorFDA-approvedSecond-line
Imfinzi
Generic name: durvalumab
How it works
Blocks the PD-1 protein on immune cells, allowing them to recognize and attack cancer cells.
Cancer types
Lung Cancer— All patients
Melanoma— All patients
Efficacy
In clinical trials, patients treated with Imfinzi had a median overall survival of approximately 16.8 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Treatment Combination Shows Promise for Lung Cancer Patients | Lung Cancer | phase-2 | The combination regimen demonstrated an objective response rate of 73.3% and a median overall survival of 14.6 months. | Source → |
| Durvalumab's Effectiveness in Lung Cancer Treatment | Lung Cancer | meta-analysis | — | Source → |
| New Study Compares Lung Cancer Treatments | Lung Cancer | phase-3 | Median IRF-assessed PFS in PD-L1+ patients was 19.4 months with tiragolumab plus atezolizumab versus 16.6 months with durvalumab. | Source → |
| Testing Durvalumab and Tremelimumab for Non-Small-Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| New Study Tests Treatment for Rare Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Durvalumab Improves Lung Cancer Survival in Real-World Study | Lung Cancer | observational | Median progression-free survival was 18.6 months with durvalumab consolidation, compared to 7.5 months without. | Source → |
| Testing Ceralasertib and Durvalumab in Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing New Treatments for Aggressive Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Durvalumab Shows Promise in Treating Early-Stage Lung Cancer | Lung Cancer | meta-analysis | Durvalumab treatment showed a significant trend toward improvement of event-free survival (HR 0.69; 95% CI: 0.61-0.78; I = 0%). | Source → |
| Testing Olaparib and Durvalumab in HER2 Negative BRCAm Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Long-term response to cancer treatment in older adult | Lung Cancer | observational | — | Source → |
| Testing Ceralasertib and Durvalumab for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing NKTR-255 and Durvalumab in Lung Cancer Patients After Chemoradiotherapy | Lung Cancer | phase-2 | — | Source → |
| Durvalumab Improves Survival in Some Lung Cancer Patients | Lung Cancer | observational | Median overall survival was 27.3, 15.1, and 23.4 months for PD-L1-positive patients with and without durvalumab and PD-L1-negative patients, respectively. | Source → |
| Ovarian Cancer Study Examines Durvalumab and Chemotherapy Combination | Ovarian Cancer | phase-1 | — | Source → |
| Durvalumab and Chemotherapy Combination for Advanced Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| Calderasib and Durvalumab Tested in Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| New Lung Cancer Treatment Shows Promise in Real-World Study | Lung Cancer | observational | The median progression-free survival was 16.0 months, and the median overall survival was 37.5 months. | Source → |
| New Insights into Lung Cancer Treatment with Durvalumab | Lung Cancer | observational | The median progression-free survival in the overall population was 24.2 months, and the 3-year progression-free survival rate was 38.9%. | Source → |
| Testing Tarlatamab and ZL-1310 in Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing a Combination Treatment for Advanced Triple-Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Investigating Durvalumab and Oleclumab for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Savolitinib and Durvalumab Combination for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Durvalumab After Chemoradiation Therapy for Limited Stage Small-Cell Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Testing Durvalumab and Radiation Therapy for Early-stage Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Chemo-Immunotherapy for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Durvalumab Side Effects in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Testing Durvalumab and Tremelimumab in Metastatic Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing New Treatments for Advanced Triple-Negative Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Durvalumab Maintenance in Frail Small Cell Lung Cancer Patients | Lung Cancer | phase-2 | — | Source → |
| Assessing Durvalumab and Domvanalimab in Stage III Unresectable NSCLC | Lung Cancer | phase-3 | — | Source → |
| Testing Durvalumab and Radiation Therapy in Early Stage Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Durvalumab, Trastuzumab, and Pertuzumab in HER2-Enriched Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Combination Therapy for Resectable Pancreatic Cancer Before Surgery | Pancreatic Cancer | phase-2 | — | Source → |
| Testing Ceralasertib in Combination with Other Treatments for Various Cancers | Prostate Cancer | phase-2 | — | Source → |
| Study of AZD2811 and Durvalumab in Small-Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Evaluating Pumitamig and Durvalumab in Lung Cancer Treatment | Lung Cancer | phase-3 | — | Source → |
| Testing Radiotherapy and Immunotherapy for Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| New Cancer Treatment Combination Shows Promise in Lung and Head and Neck Cancers | Lung Cancer | phase-1 | Five (8.3%) patients had objective responses; 31 (51.7%) had stable disease. | Source → |
| Durvalumab as Consolidation for Limited Stage Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Combining two treatments for advanced prostate cancer | Prostate Cancer | phase-2 | Median radiographic progression-free survival was 5.0 months, and median overall survival was 19.1 months. | Source → |
| Durvalumab and Chemotherapy Tested in Lung Cancer Patients | Lung Cancer | phase-2 | Confirmed ORR was 16% (80% confidence interval: 7-30); response was maintained for more than 6 months in the four patients with confirmed response. | Source → |
| Triplet Combination of Targeted Immunotherapeutic Agents for Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Durvalumab Study for Unresectable Lung Cancer in Russia | Lung Cancer | preclinical | — | Source → |
| Durvalumab's Effect on Lung Cancer Recurrence After Chemotherapy and Radiation | Lung Cancer | phase-3 | Durvalumab receipt was associated with improved PFS (median 16 vs. 11 months, P = .011) and improved OS (median 50 vs. 30 months, P = .042). | Source → |
| Combining Chemotherapy and Immunotherapy for Lung Cancer | Lung Cancer | phase-2 | N2 nodal clearance was 73.3% (22/30) after treatment. | Source → |
| Timing of Durvalumab Treatment Affects Lung Cancer Survival | Lung Cancer | observational | When considering the timing of durvalumab, no significant survival difference was found when durvalumab was initiated on or before week 4: adjusted HR, 0.81 (95% CI, 0.62 to 1.05, = .07). | Source → |
| New Treatment Combination Shows Promise for Ovarian Cancer Patients | Ovarian Cancer | phase-2 | PFS36 rates are 47.4% (olaparib priming then olaparib-durvalumab), 48.7% (olaparib-cyclophosphamide then olaparib-durvalumab), and 35.1% (olaparib monotherapy). | Source → |
| Durvalumab and Radiation Therapy Improve Lung Cancer Outcomes | Lung Cancer | phase-3 | The 2- and 3-year local control rates in patients who received total radiation doses > 66 Gy were 80% and 75%, respectively. | Source → |
| Rare Cancer Linked to New Lung Cancer Treatment | Leukemia | observational | — | Source → |
| Durvalumab as Consolidation Therapy for Lung Cancer Patients in Brazil | Lung Cancer | observational | Median progression-free survival was 9.9 months, with a 36 month-PFS of 34.5%. | Source → |
| New Lung Cancer Treatment Shows Promise After Surgery | Lung Cancer | observational | The IPTW-adjusted median progression-free survival was 25.4 months for the CRT-D group, and 11.5 months for the CRT group. | Source → |
| Durvalumab with Radiation Therapy in Lung Cancer: Early Results | Lung Cancer | phase-2 | The primary endpoint of progression-free survival at 12 months was 20%. | Source → |
| Durvalumab Outcomes in Stage III Lung Cancer Patients | Lung Cancer | observational | The 4-year overall survival rate was 53% overall, and 67% for patients with a PD-L1 score of ≧50%. | Source → |
| Durvalumab treatment for lung cancer patients shows promising results | Lung Cancer | observational | Median progression-free survival was 16.7 months (95% CI 12.2-25). | Source → |
| Durvalumab Works in Elderly Lung Cancer Patients, but Side Effects are More Common | Lung Cancer | observational | The median progression-free survival was 17.7 months in patients aged 70 years or older, and 19.4 months in younger patients. | Source → |
| New Trial Explores Combination Therapy for Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| New Biomarker May Predict Lung Cancer Treatment Side Effect | Lung Cancer | lab-study | Patients with high levels of EV-RELA had a 53.8% incidence of symptomatic pneumonitis, compared to 13.4% in those with low levels. | Source → |
| Durvalumab Linked to Rare Neurological Side Effects in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Combining Eribulin and Durvalumab in Advanced Breast and Ovarian Cancer | Ovarian Cancer | phase-1/2 | The overall response rate was 55%, and median progression-free survival was 6.2 months, with median overall survival of 15.0 months. | Source → |
| Durvalumab Efficacy Similar in Black and Non-Black Lung Cancer Patients | Lung Cancer | phase-3 | The median overall survival was not-reached in Black patients and 39.7 months in non-Black patients. | Source → |
| Durvalumab and Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer | Breast Cancer | phase-1/2 | pCR rates were similar between Black (43%) and non-Black patients (48%; P = 0.71). | Source → |
| Researchers Treat Pneumonitis with Infliximab in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Durvalumab-based treatment helps some patients with lung cancer transformation | Lung Cancer | observational | — | Source → |
| Hispanic Patients with Lung Cancer May Have Poorer Outcomes with Durvalumab Treatment | Lung Cancer | observational | Hispanic patients had a 20% reduction in survival compared to non-Hispanic White patients and a 42% reduction compared to the PACIFIC trial group. | Source → |
| Durvalumab after Chemotherapy and Radiation Works in Real-World Lung Cancer Patients | Lung Cancer | meta-analysis | The pooled 12-month overall survival rate was 90% (95% confidence interval [CI], 83%-98%) and the pooled 12-month progression-free survival rate was 62% (95% CI, 56%-68%). | Source → |
| Combining two treatments shows promise for melanoma patients | Melanoma | phase-2 | The overall response rate was 31.0% and the disease control rate was 63.3%. | Source → |
| Combining Immunotherapies to Treat Colorectal Cancer Liver Metastases | Colorectal Cancer | phase-1 | The median relapse-free survival was 9.7 months, and overall survival was 24.5 months. | Source → |
| Durvalumab May Not Be as Effective for Some Lung Cancer Patients | Lung Cancer | observational | Patients in the ERBB2/EGFR cohort had a significantly shorter disease-free survival compared with the EGFR or ERBB2 wild-type cohort (7.5 mo versus not reached, p = 0.04). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.